drugset / Trial / NCT05036226

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT05036226

Phase 1/2 Recruiting 76 enrolled Medical University of South Carolina
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

Timeline

Start
2022-03-03
Primary completion
2027-05-21
Completion
2028-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 600 mg Oral
Subject Metformin Small molecule 1000 mg Oral
Subject Nelfinavir Other / unclassified 1250 mg Oral
Subject Nelfinavir Other / unclassified 2500 mg Oral
Subject Sirolimus Small molecule 0.5 mg Oral
Subject dasatinib anhydrous Small molecule 20 mg Oral

Indications